What is it about?
Sodium–glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin (EMPA), are used to treat diabetes type 2. They are thought to have anti-tumor effects by acting on tumor metabolism and growth. This study shows that EMPA has ambivalent effects on different colorectal cancer cell lines.
Featured Image
Why is it important?
It is highly relevant for cancer treatment to understand the mechanisms by which SGLT2 inhibitors can have anti-tumor effects.
Perspectives
Further research is needed to determine the relevance of this drug class in cancer treatment within a precision medicine context.
Dr Angel Cid Arregui
Asteriapharma
Read the Original
This page is a summary of: Cell line-specific modulation of colorectal cancer cell behavior following SGLT2 inhibition via empagliflozin, Scientific Reports, August 2026, Springer Science + Business Media,
DOI: 10.1038/s41598-026-63577-x.
You can read the full text:
Contributors
The following have contributed to this page
